• Zhaoshun Jiang, Songbin Liu, Lan Wang, Wanling Li, Cheng Li, Feifei Lang, Ruoxi Li, Yue Zhou, Jiajun Wu, Yuxi Cai, Wen Xu, Zhen Chen, Zhijun Bao, Ming Li, and Weidong Gu.
• Department of Anesthesiology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
• BMC Anesthesiol. 2023 Aug 8; 23 (1): 265265.

BackgroundThere is the ongoing debate over the effect of inspired oxygen fraction (FiO2) during mechanical ventilation on postoperative atelectasis. We aimed to compare the effects of low (30%) and moderate (60%) FiO2 on postoperative atelectasis. The hypothesis of the study was that 30% FiO2 during mechanical ventilation could reduce postoperative atelectasis volume compared with 60% FiO2.MethodsWe performed a randomized controlled trial with 120 patients. Subjects were randomly assigned to receive 30% or 60% FiO2 during mechanical ventilation in a 1:1 ratio. The primary outcome was the percentage of postoperative atelectasis volume in the total lung measured using chest CT within 30 min after extubation. The secondary outcomes included different aeration region volumes, incidence of clinically significant atelectasis, and oxygenation index.ResultsIn total, 113 subjects completed the trial, including 55 and 58 subjects in the 30% and 60% FiO2 groups, respectively. The percentage of the postoperative atelectasis volume in the 30% FiO2 group did not differ from that in the 60% FiO2 group. Furthermore, there was no significant difference in the atelectasis volume between the two groups after the missing data were imputed by multiple imputation. Additionally, there were no significant differences in the volumes of the over-aeration, normal-aeration, and poor-aeration regions between the groups. No significant differences in the incidence of clinically significant atelectasis or oxygenation index at the end of surgery were observed between the groups.ConclusionsCompared with 60% FiO2, the use of 30% FiO2 during mechanical ventilation does not reduce the postoperative atelectasis volume.Trial RegistrationChinese Clinical Trial Registry ( http://www.chictr.org.cn ). Identifier: ChiCTR1900021635. Date: 2 March 2019. Principal invetigator: Weidong Gu.© 2023. BioMed Central Ltd., part of Springer Nature.

18 keywords...

hide…